Advertisement


Amir A. Jazaeri, MD, on Metastatic Cervical Cancer: The Role of Immunotherapy

SGO 2021 Virtual Annual Meeting on Womens Cancer

Advertisement

Amir A. Jazaeri, MD, of The University of Texas MD Anderson Cancer Center, discusses data on the safety and efficacy of adoptive cell transfer using autologous tumor-infiltrating lymphocytes (LN-145) to treat patients with recurrent, metastatic, or persistent cervical carcinoma whose tumors have progressed on prior systemic therapy (ID # 10224).



Related Videos

Gynecologic Cancers

Rebecca S. Kristeleit, MD, PhD, on Relapsed Ovarian Cancer: Rucaparib vs Chemotherapy

Rebecca S. Kristeleit, MD, PhD, of the University College London and UCL Cancer Institute, discusses efficacy and safety results from the phase III ARIEL4 study, which showed that rucaparib improved progression-free survival vs standard-of-care chemotherapy in patients with BRCA-mutated, platinum-resistant, or platinum-sensitive relapsed ovarian cancer (ID #10191).

Gynecologic Cancers
Global Cancer Care

Edward L. Trimble, MD, MPH, on Cervical Cancer: A Global WHO Initiative

Edward L. Trimble, MD, MPH, of the National Cancer Institute, discusses the World Health Organization’s global strategy to speed the elimination of cervical cancer through vaccination, screening, treatment, and training for multidisciplinary teams in gynecologic oncology care. This marks the first time that 194 countries have committed to such an effort (ID # 10203).

Gynecologic Cancers
Genomics/Genetics

William H. Bradley, MD, on Ovarian Cancer: 5-Year Follow-up on Maintenance Olaparib

William H. Bradley, MD, of the Medical College of Wisconsin, discusses results from the SOLO-1 trial on maintenance olaparib after first-line platinum-based chemotherapy for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation. Almost half of the patients treated with olaparib in the study were disease-free at 5 years, vs 20% of those treated with placebo (ID# 10224).

Gynecologic Cancers

Shannon N. Westin, MD, on Treating Endometrial Cancer With Enzalutamide, Paclitaxel, and Carboplatin

Shannon N. Westin, MD, of The University of Texas MD Anderson Cancer Center, discusses phase II results from the ENPAC trial, which showed the combination of enzalutamide, paclitaxel, and carboplatin yielded promising clinical outcomes in chemotherapy-naive advanced or recurrent endometrioid cancer (ID # 10244).

Gynecologic Cancers

Andreas Obermair, MD, on Treating Endometrial Adenocarcinoma With a Levonorgestrel Intrauterine Device

Andreas Obermair, MD, of the University of Queensland and Queensland Centre for Gynaecological Cancer Research, discusses data on a hormonal IUD used to treat women with the precursor lesion endometrial hyperplasia with atypia (EHA) and those with stage I endometrial adenocarcinoma (EAC). At 6 months, the data showed a complete pathologic response in 82% of patients with EHA and in 43% of those with EAC (ID# 10244).

Advertisement

Advertisement




Advertisement